Journal
MOLECULAR IMMUNOLOGY
Volume 48, Issue 9-10, Pages 1209-1215Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2011.03.001
Keywords
Human TIPE2 (tumor necrosis factor-alpha-induced protein 8-like 2); Expression; Immunohistochemistry (IHC); Flow cytometry; Western blot
Categories
Funding
- National Natural Science Foundation of China [30872309, 81072407, 81071705]
- National 973 program of China [2006CB503803]
- Award Funds for Excellent Young and Middle-aged Scientists of Shandong Province [BS2009YY002]
Ask authors/readers for more resources
TIPE2 (tumor necrosis factor-alpha-induced protein 8-like 2, or TNFAIP8L2) is a newly identified negative regulator of innate and adaptive immunity. TIPE2 deficiency in mice leads to systemic inflammation and TIPE2 down-regulation in humans is associated with autoimmunity. However, the nature of human TIPE2-expressing cells in various tissues has not been characterized due to the lack of suitable antibodies. In the present study, we generated specific rabbit antibodies against human TIPE2 and examined human TIPE2 expression in various tissues by Western blot, flow cytometry, and immunohistochemistry. We found that unlike murine TIPE2 that is preferentially expressed by hematopoietic cells, human TIPE2 was also expressed in a wide variety of non-hematopoietic cell types, including hepatocytes, neurons in brain and brainstem, squamous epithelial cells in esophagus and cervix, transitional epithelial cells in bladder and ureter, and glandular epithelial cells in stomach, colon and appendix. For squamous epithelium, the level of TIPE2 expression increased dramatically in terminally differentiated cells with the proliferating precursor cells completely devoid of TIPE2. The unique expressional profile of human TIPE2 suggests new functions beyond controlling innate and adaptive immunity. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available